- According to Business Wire, on September 12, 2016, Samsung Bioepis announced that it has added Canada to its growing list of jurisdictions in which it has received regulatory approval for its biosimilar of Amgen’s Enbrel® (etanercept). The biosimilar will be marketed in Canada under the brand Brenzys® as a treatment for rheumatoid arthritis and ankylosing spondylitis.
- According to The Korea Times, earlier this month, Samsung Bioepis launched its biosimilar of Janssen’s Remicade® (infliximab) in the United Kingdom. Samsung Bioepis received European regulatory approval for its biosimilar, under the brand Flixabi™, this past May.
Blog Big Molecule Watch September 15, 2016